The tumour susceptibility gene 101 (TSG101) is reported to play important roles in the development and progression of several human cancers. However, its potential roles and underlined mechanisms in human hepatocellular carcinoma (HCC) are still needed to be further clarified. In the present study, we reported that knock down interacted with PEG10 and protected it from proteasomal degradation thereby regulating the expression of p53, p21 and MMPs. Finally, we found that both TSG101 and PEG10 proteins are up-regulated and presented a direct correlation in HCC patients. In conclusion, these results suggest that TSG101 is up-regulated in human HCC patients, which may accelerate the proliferation, migration and invasion of HCC cells through regulating PEG10.
| INTRODUCTION
Hepatocellular carcinoma is one of the leading causes of cancer death worldwide. Despite the great advances in diagnosis and treatment in the past decade, the outcome of patients with HCC is still very poor. [1] [2] [3] [4] Curing this intractable disease therefore requires a profound understanding of the mechanisms underlying its pathogenesis, which is critical to identify specific molecular targets that could be served as a treatment for HCC.
TSG101, an important member of the ESCRT-I (endosomal complexes required for transport), has been shown to be involved in many cellular processes, such as endosomal trafficking, ubiquitination, virus budding and cell survival. [5] [6] [7] [8] [9] Biochemical studies have identified that TSG101 can regulate the protein ubiquitination by interacting with many ubiquitin ligases, such as Tal, 10, 11 MGRN1, 12, 13 MDM2. 14, 15 Recently, it is reported that TSG101 plays important roles in the development and progression of human cancers. For example, the expression of TSG101 is frequently up-regulated in human ovarian cancer, colorectal carcinoma, papillary thyroid carcinoma, gastrointestinal tumour, and gallbladder cancer, [16] [17] [18] [19] [20] thus it could be served as a biomarker in several human cancers. Overexpression of TSG101 in cancers is found to activate multiple important pathways, including PI3K/Akt and MAPK/ERK pathways. 21 In addition, TSG101 is reported to play a role in promoting HCC cell growth, 22 however, the underlined mechanism and the potential role of TSG101 in human HCC migration and invasion remains unknown, which should be fully clarified.
PEG10, also known as EDR, HB-1, Mar2, MEF3L, Mart2, and RGAG3, is expressed not only in brain, kidney, and lung tissues in adults but also in embryonic tissues, such as placenta. 23 It has been demonstrated that multiple roles have been attributed to PEG10, for example, it involves in cell proliferation, 24 ,25 inhibition of cell apoptosis 26 and promotion of migration and invasion. 27 In addition, some studies have indicated that PEG10 is frequently overexpressed in multiple malignancies, such as lung cancer, hepatocellular carcinoma, B-cell chronic lymphocytic leukemia and pancreatic cancer. [27] [28] [29] [30] The overexpression of PEG10 is significantly associated with the proliferation, migration and metastasis of such malignancies.
In this study, we observed the expression of TSG101 protein in HCC tissues and investigated the roles of TSG101 in the proliferation, migration and invasion of HCC cells. We provided evidence that TSG101 promotes the proliferation, migration and invasion of HCC cells through regulating the expression of PEG10.
| MATERIALS AND METHODS

| Antibodies
TSG101, PEG10, TIMP1, MMP2, MMP7, MMP9 and FLAG antibodies were bought from Abcam (Cambridge, UK). Antibodies against p53, p21 and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). 
| Tissue samples
| Constructs and production of the lentivirus
For silencing of TSG101, three shRNA duplexes were designed as follows:
shTSG101#1-F:
GATCGCAGTTCCAGGGAACTAATTTCAAGAGAAT- AATTCAAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGT-
GACACGTTCGGAGAA
The shRNA oligomers and nontargeting oligomers (control) were annealed and then subcloned into the pLV-shRNA vector by the BamH I and EcoR I cloning sites. Cell transfection was performed with a PolyJet (SignaGen, Gaithersburg, MD, USA) as described in the manufacturer's protocol. Cell transfection was carried out by PolyJet (SignaGen, Gaithersburg, MD, USA) according to the manufacturer's instructions. The lentiviruses were produced by co-transfecting the core plasmid and the packaging plasmids in 293T cells.
| Establishment of the stable cell lines
The establishment of stable cell lines was performed as we previously described. 31, 32 For stably silencing of TSG101, HepG2 and SMMC-7721 cells were infected by control and shTSG101#3 viruses, respectively. Forty-eight hours after infection, the cells were continuously cultured in the medium containing 2.5 μg/mL puromycin LIU ET AL.
| 71 (Sigma, St. Louis, MO, USA). The surviving cells were cultured into cell lines stably expressing control and shTSG101#3.
| Transient overexpression of TSG101
The TSG101 construct was generated by cloning the human TSG101 cDNA into the expression vector p3XFLAG-CMV-14 at the Hind III and Kpn I restriction sites. Transfection of TSG101 was performed using the PolyJet transfection reagent according to the manufacturer's instructions.
| EdU assay
The effect of TSG101 on the proliferation of HepG2 and SMMC- 
| Cell viability assay
The cell viability was assessed via cell counting kit-8 assay (CCK-8, Dojindo, Janpa 
| Wound healing assay
The migration function of cells was evaluated using wound healing assay. The cells were seeded in 6-well plates. Then, the scratches were developed in the middle of the wells with a pipette tip. The cells were washed with PBS to remove the debris and incubated in serum-free media for 48 hours. At the designated time, five randomly selected fields were acquired under an inverted microscope (Olympus). The number of cells across the wound was normalised to the control group.
| Transwell invasion and migration assays
Transwell assays were performed with a polycarbonate filter membrane with a diameter of 6.5 mm and pore size of 8 μm ( 
| Western blotting
The cells were lysed in RIPA buffer and centrifuged at 12 000 g for 10 minutes at 4°C. The supernatants were collected for Western blotting assay. Equal amount of proteins was subjected to 10% SDS-PAGE and then transferred to 0.45-μm pore size PVDF membrane (Millipore, Billerica, MA, USA). After blocking with 5% nonfat milk, the membrane was probed with primary antibodies (TSG101, FLAG, PEG10, TIMP1, MMPs, p53, p21 and β-actin) at 4°C overnight and secondary antibodies at room temperature for 1 hour. Bound antibodies were detected by the ECL Plus western blotting substrate (Thermo Fisher, Waltham, MA, USA) and detected by enhanced chemiluminescence detection system (Thermo Fisher). Band densities were quantified by Image J Software. The relative amount of proteins was determined by normalizing the densitometry value of interest to that of the loading control.
F I G U R E 1 Down-regulation of TSG101 inhibits HCC cell proliferation. A, TCGA database analysis showed high levels of TSG101 were associated with poor prognosis in HCC patients. B, Representative blots and quantification of shTSG101 sefficiency. C, Quantification of the EdU incorporation assay performed in HepG2 and SMMC-7721 cells upon knocking down of TSG101. D, Quantification of the colony formation assay with TSG101 silenced HepG2 and SMMC-7721. E and F, CCK8 assay results. G, Representative bolts and H, quantification to show the protein levels of p53 and p21 in TSG101 silenced HepG2 and SMMC-7721 cells. *P < 0.05, **P < 0.01, ***P < 0.001
The cells were transiently transfected with the indicated plasmids.
Twenty-four hours after transfection, the cells were lysed in a Triton-X-100-based lysis buffer (1% Triton- The immunoprecipitates were washed five times in lysis buffer, and proteins were recovered by boiling the beads in an SDS sample buffer and analysed by western blotting.
| Immunohistochemistry
Immunohistochemical staining was performed using the protocol supplied by the S-P immunohistochemistry kit (Zhongshan Goldenbridge Biotech CO., Beijing, China). The sections were fixed with 4%
paraformaldehyde and blocked with 10% goat serum. Then, the sections were incubated with TSG101 or PEG10 antibody followed by
Biotin-conjugated goat anti-rabbit IgG and HRP-conjugated streptavidin. The reaction was developed by 3, 3′-diaminobenzidine (DAB) chromogenic reagent (Zhongshan Goldenbridge Biotech CO.). The sections were counterstained with hematoxylin to stain the nucleus and dehydrated by incubation in increasing concentrations of alcohol, followed by 100% xylene. Finally, the cover slips were mounted onto the slides with neutral gum. The photos were collected under an Olympus IX-71 microscope (Olympus). The images were processed by Image-Pro-Plus 6.0 software, and the mean optical density (MOD) represented the expression level of TSG101 and PEG10.
| Statistical analysis
The results shown were representative of experiments that repeated at least three times. All the quantitative data was presented as mean ± SEM. Statistical analysis was performed with the SPSS Version 13.0 (SPSS Inc, Chicago, IL, USA). Differences in multiple groups were compared by a one-way analysis of variance (ANOVA) followed by post hoc test. Differences between two groups were determined by Student's t test. P < 0.05 were considered statistically significant (*P < 0.05). Firstly, we down-regulated TSG101 expression by using its specific shRNA and observed its effects on cell proliferation, migration and invasion. To knock down TSG101, three shRNA targets (shTSG101#1, shTSG101#2 and shTSG101#3) were subcloned into a lentiviral vector pLV-shRNA, a control shRNA served as a negative control. Then, we determined their silencing efficiency in suppressing TSG101 expression. As Figure 1B Figure S2A , Figure 1C ). The ability of colony formation was also obviously suppressed by silencing of TSG101, comparing with the control group ( Figure S2B , Figure 1D ).
In addition, the CCK-8 assay showed the cell viability was reduced upon knocking down of TSG101 ( Figure 1E,F) . Correspondingly, cell cycle related proteins, like p53 and p21 were significantly increased after down-regulation of TSG101 ( Figure 1G,H) . Next, we analysed the cell migration and invasion upon knocking down of TSG101. As shown in Figure S2C , Figure 2A , was confirmed by Western blotting ( Figure 3A) . Then, we asked whether the cell proliferation, migration and invasion were aggravated upon TSG101 overexpression. Therefore, 24 hours after transfection, the cells were used to evaluate the cell growth and motility.
The EdU incorporation assay showed that, compared with the 3*FLAG group, EdU-positive cells of the 3*FLAG-TSG101 group increased by 34.2% and 24.6% in HepG2 and SMMC-7721 cells, respectively ( Figure S3A , Figure 3B ). The ability of colony formation was also obviously increased upon transfecting with 3*FLAG-TSG101, comparing with the 3*FLAG group ( Figure S3B , Figure 3C ).
In addition, the CCK-8 assay revealed that the proliferation rate of the 3*FLAG-TSG101 group was significantly increased ( Figure 3D ,E).
Correspondingly, p53 and p21 were significantly decreased after overexpression of TSG101 ( Figure 3F,G) . Subsequently, we examined the cell migration and invasion upon overexpression of TSG101. As shown in Figure S3C and Figure 4A , the wound healing assay indicated that, compared with the control group, the number of migratory cells was approximately increased by 77% and 75% HepG2 and SMMC-7721 cells, respectively. To exclude the effect of cell proliferation induced by TSG101 overexpression on cell migration and invasion assays, we performed the transwell assays in the presence of a proliferation blocker, CDK2 inhibitor (K03861). The transwell migration assay (-Matrigel) obtained similar results with the wound healing assay ( Figure S3D , Figure 4B ). In addition, the transwell invasion assay (+Matrigel) displayed that the number of invasive cells increased by 80% and 170% in HepG2 and SMMC-7721 cells, respectively ( Figure S3E , Figure 4C ). Correspondingly, MMP2, MMP7
and MMP9 were significantly increased and TIMP1 was decreased after overexpression of TSG101 ( Figure 4D-H) . These results further suggest that TSG101 is involved in the proliferation, migration and invasion of HCC cells and overexpression of TSG101 promotes the proliferation, migration and invasion of HCC cells. 
| TSG101 stabilizes PEG10 by protecting it from proteasomal degradation
To address how TSG101 regulates PEG10, we firstly explored the interaction between TSG101 and PEG10. It was found that FLAG tagged TSG101 interacted with Myc tagged PEG10 in HEK293
and HepG2 cells ( Figure 6A,B) . Also, the endogenous TSG101 and PEG10 formed into a complex in HepG2 cells ( Figure 6C ). Since it has been reported that TSG101 is frequently involved in protein ubiquitination and degradation, we thought whether TSG101 is involved in regulating the stability of PEG10. To answer this question, we treated the TSG101 silenced cells with proteasome inhibitor MG-132, and found that MG-132 could block the degradation of PEG10 in TSG101 down-regulated cells ( Figure 6D , E). Then, we treated the cells with cycloheximide (CHX), a protein synthesis inhibitor, and detected the stability of PEG10 upon knocking down or overexpressing of TSG101. It was showed that F I G U R E 6 TSG101 interacts with and stabilizes PEG10 by protecting it from proteasomal degradation. A, Coimmunoprecipitation assay showed that FLAG tagged TSG101 interacted with Myc tagged PEG10 in HEK293. B, Endogenous TSG101 and PEG10 formed into a complex in HepG2 cells. C, Representative bolts and D, quantification showed proteasome inhibitor MG-132 could block the degradation of PEG10 in TSG101 down-regulated cells. E and F, Representative bolts and quantification showed knock down of TSG101 decreased the stability of PEG10. G and H, Representative bolts and quantification showed overexpression of TSG101 increased the stability of PEG10. *P < 0.05, **P < 0.01, ***P < 0.001 PEG10 was much more unstable upon knocking down of TSG101 in HepG2 and SMMC-7721 cells ( Figure 6F,G) , however, the stability was significantly increased by overexpressing of TSG101 in HepG2 and SMMC-7721 cells ( Figure 6H,I ).
| TSG101 and PEG10 are up-regulated and correlated in HCC patients
Finally, we studied the clinical relevance of TSG101 and PEG10 and their relationship in clinical HCC patients. As is shown in Figures 7A,   B , the protein level of TSG101 and PEG10 in HCC samples was approximately 3-6 folds higher than those of non-tumour tissues.
Next, we analyzed the correlation between TSG101 and PEG10 and found that there was a direct correlation between TSG101 and PEG10 levels in non-tumour tissues and HCC patients (r = 0.63, P < 0.001; Figure 7C ). In addition, we assessed the expression and distribution of TSG101 and PEG10 in non-tumour tissues and HCC patients by immunohistochemistry. Similarly, the expression of TSG101 and PEG10 in HCC tissues were significantly increased compared with the non-tumour tissues, which was in line with our F I G U R E 7 Expression of TSG101 and PEG10 in human HCC patients. A, Total proteins isolated from non-tumor and HCC tissues were analyzed by Western blotting for assessment of TSG101 and PEG10. B, Statistical chart showed the expression levels of TSG101 and PEG10 in non-tumor and HCC tissues. The ratios indicate the levels of TSG101 and PEG10 to β-actin levels with respect to each sample. C, The correlation of TSG101 expression with PEG10 in non-tumor and HCC tissues. r = 0.63; P < 0.001. D, Representative images of TSG101 and PEG10 from nontumor and HCC tissues determined by immunohistochemistry, Bar = 50 μm. E, The histogram showed the quantitative analysis of the relative level of TSG101 and PEG10. * P < 0.05, ** P < 0.01, *** P < 0.001 results found above ( Figure 7D,E) . Collectively, these results suggest that TSG101 and PEG10 are up-regulated in human HCC patients and further confirm the positive correlation between TSG101 and PEG10 levels.
| DISCUSSION
TSG101 is a cancer-related protein that has been reported to play important roles in many cellular processes, including endosomal trafficking, ubiquitination, virus budding and cell survival. [5] [6] [7] [8] [9] Recently, it is found that the expression of TSG101 is frequently up-regulated in human ovarian cancer, colorectal carcinoma, papillary thyroid carcinoma, gastrointestinal tumour, and gallbladder cancer, 16-20 which indicates that TSG101 could be a potential biomarker in human cancers. However, the expression pattern in human HCC has not yet been clarified. In our present study, we detected the protein expression of TSG101 in HCC tissues and non-tumour liver tissues. We discovered that TSG101 protein was expressed increasingly in the patients with HCC, comparing with the non-tumour liver tissues. We also analyzed the effects of TSG101 on the proliferation, migration and invasion of HCC cells and found that down-regulating of TSG101 inhibited the cell proliferation, migration and invasion, whereas overexpression of TSG101 promoted them. These results suggest that TSG101 exerts a tumour-promoting role in HCC and might be acted as a potential biomarker for HCC.
It is well known that depression of specific tumour suppressor genes or activation of specific oncogenes is a key event for the development and malignant progression of HCC. 31, [35] [36] [37] This usually includes, on the one hand, any gain-of function mutation or up-regulation of the upstream activators, and, on the other hand, any loss-of function mutation or down-regulation of the upstream inhibitors.
TSG101 has been shown to regulate the Akt and ERK proteins. 21, 22 In this study, we have provided the evidence that TSG101 is involved in the regulation of another oncogenic protein, PEG10. We showed that TSG101 and PEG10 forms into a complex in HCC cells, and TSG101 could increase the protein stability of PEG10 by protecting it from proteasomal degradation, thereby promoting the proliferation, migration and invasion of HCC cells through regulating the expression of cell cycle related regulatory factors and the MMPs.
Interestingly, it was also found that both TSG101 and PEG10 proteins are up-regulated in HCC patients. Moreover, there was a direct correlation between TSG101 and PEG10 protein levels. In this case, we conclude that abnormal expression of TSG101 in human HCC patients will cause the up-regulation of PEG10, which will facilitate the proliferation, migration and invasion of HCC. Therefore, up-regulation of TSG101 may be an important event in the development and malignant progression of HCC.
In conclusion, we have firstly supplied the evidences linking 
